Advances in imaging of tuberculosis: The role of 18F-FDG PET and PET/CT

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 287-293

  Vorster, Mariza ^a   Sathekge, Mike M ^a   Bomanji, Jamshed ^b  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

fluorine 18 fluorodeoxyglucose; PET computed tomography; tuberculosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PLEURA EFFUSION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; FEMALE; GRANULOMA; LUNG TUMOR; MALE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TUBERCULOSIS;

DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GRANULOMA; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS;

EID: 84897582592     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000043     Document Type: Review

References (50)

1. Mendelson M. Diagnosing tuberculosis in HIV-infected patients: challenges and future prospects. Br Med Bull 2006; 81-82:149-165.
2. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med 1998; 28:352-358.
3. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36:1854-1861.
4. Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006; 7:57-69.
5. Suga K, Kawakami Y, Hiyama A, et al. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid nonsmall cell lung cancer and benign lesions. Bull Cancer 2009; 23:427-435.
6. Kim D-W, Park S-A, Kim CG. Dual-time-point positron emission tomography findings of benign mediastinal fluorine-18-fluorodeoxyglucose uptake in tuberculosis-endemic region. Indian J Nucl Med 2011; 26:3-6.
7. Barger RL Jr, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 2012; 19:153-158.
8. Cloran FJ, Banks KP, Song WS, et al. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 2010; 68:66-71.
9. Bental MM, Deutsch CC. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med 1993; 29:317-326.
10. Marjanovic S, Skog S, Heiden T, et al. Expression of glycolytic isoenzymes in activated human peripheral lymphocytes: cell cycle analysis using flow cytometry. Exp Cell Res 1991; 193:425-431.
11. Soussan M, Brillet P-Y, Mekinian A, et al. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 2012; 81:2872-2876.
12. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216:117-121.
13. Kim I-J, Lee JS, Kim S-J, et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 2007; 35:808-814.
14. Sathekge MM, Maes A, Pottel H, et al. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 2010; 100:598-601.
15. Chen C-J, Lee B-F, Yao W-J, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol 2008; 191:475-479.
16. Kaneko K, Sadashima S, Irie K, et al. Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging. Ann Nucl Med 2013; 27:329-339.
17. Heysell SK, Thomas TA, Sifri CD, et al. 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med 2013; 21:13-14.
18. Shinohara T, Shiota N, Kume M, et al. Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma. BMC Infect Dis 2013; 13:12.
19. Global tuberculosis, control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization; 2008.
20. Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009; 49:1350-1357.
21. Arciniegas WW, Orjuela DLD. Extrapulmonary tuberculosis: a review of 102 cases in Pereira, Colombia. Biomedica 2006; 26:71-81.
22. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005; 72:1761-1768.
23. Sathekge M, Maes A, D'Asseler Y, et al. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 2012; 39:1184-1190.
24. Dong A, Dong H, Wang Y, et al. (18)F-FDG PET/CT in differentiating acute tuberculous from idiopathic pericarditis: preliminary study. Clin Nucl Med 2013; 38:160-165.
25. Skaf GS, Domloj NT, Fehlings MG, et al. Pyogenic spondylodiscitis: an overview. J Infect Public Health 2010; 3:5-16.
26. Kalicke T, Schmitz A, Risse JH, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med 2000; 27:524-528.
27. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749-754.
28. Lee IS, Lee JS, Kim SJ, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pyogenic and tuberculous spondylitis: preliminary study. J Comput Assist Tomogr 2009; 33:587-592.
29. Rivas-Garcia A, Sarria-Estrada S, Torrents-Odin C, et al. Imaging findings of Pott's disease. Eur Spine J 2013; 22:567-578.
30. Kim S-J, Lee JS, Suh KT, et al. Differentiation of tuberculous and pyogenic spondylitis using double phase F-18 FDG PET. Open Med Imaging J 2008; 2:1-6.
31. Gratz S, Dorner J, Fischer U, et al. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imag 2002; 29:516-524.
32. Cloyd MW, Chen JJ, Wang I. How does HIV cause AIDS? The homing theory. Mol Med Today 2000; 6:108-111.
33. Lederman MMM, Margolis LL. The lymph node in HIV pathogenesis. Semin Immunol 2008; 20:187-195.
34. Scharko AM, Perlman SB, Pyzalski RW, et al. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003; 362:959-961.
35. Wallace M, Pyzalski R, Horejsh D, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology 2000; 274:255-261.
36. Sathekge M, Maes A, Kgomo M, Van de Wiele C. Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count. Nucl Med Commun 2010; 31:137-140.
37. Sathekge M, Maes A, Kgomo M, et al. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 2011; 52:880-885.
38. Sathekge M, Buscombe Jr. Can positron emission tomography work in the African tuberculosis epidemic? Nucl Med Commun 2011; 32:241-244.
39. Park IN, Ryu JS, Shim TS. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 2007; 33:1-3.
40. Tian G, Xiao Y, Chen B, et al. FDG PET/CT for therapeutic response monitoring in multisite nonrespiratory tuberculosis. Acta Radiol 2010; 51:1002-1006.
41. Hofmeyr A, Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb) 2007; 87:459-463.
42. Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med 2013; 43:349-366.
43. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, et al. 18F-FDG PET/CT in tuberculosis: an early noninvasive marker of therapeutic response. Int J Tuberc Lung Dis 2012; 16:1180-1185.
44. Park YH, Yu CM, Kim ES, et al. Monitoring therapeutic response in a case of extrapulmonary tuberculosis by serial F-18 FDG PET/CT. Nucl Med Mol Imaging 2011; 46:69-72.
45. Heysell SK, Thomas TA, Sifri CD, et al. 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med 2013; 13:14.
46. Liu Q, Peng Z-M, Liu Q-W, et al. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J 2006; 119:634-639.
47. Hara T, Inagaki K, Kosaka N, Morita T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 2000; 41:1507-1513.
48. Hara T, Kosaka N, Suzuki T, et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124:893-901.
49. Yamamoto Y, Nishiyama Y, Kimura N, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2008; 35:236-245.
50. Yang W, Zhang Y, Fu Z, et al. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in nonsmall-cell lung cancer. Eur J Nucl Med Mol Imaging 2010; 37:1291-1299.